MedTrace Logo

Assessment of Hypoxia Before Radioembolization Treatment With 18F-FMISO PET

NCT06027021 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 64

Last updated 2024-07-30

No results posted yet for this study

Summary

Hypoxia is a known factor for resistance to radiotherapy in tumors. Response to transarterial radioembolization is known to be variable between different patients even if the same dose of radiation was delivered. In this study the investigators aim to quantify the hypoxia in the primary and secondary tumors of liver with 18F-FMISO PET before radioembolization and to prove any effect of the hypoxia, if present, on the dose that should be delivered to tumor to ensure treatment response.

Conditions

  • Radioembolization
  • Radiotherapy
  • Cancer
  • Positron Emission Tomography

Interventions

DIAGNOSTIC_TEST

18F-Fluoromisonidazole PET

Imaging of hypoxia before radioembolization with 18F-Fluoromisonidazole PET.

Sponsors & Collaborators

  • Ankara University

    lead OTHER

Principal Investigators

  • Cigdem Soydal, MD · Ankara University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-15
Primary Completion
2024-05-15
Completion
2024-07-15

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06027021 on ClinicalTrials.gov